Humana Tops Quarterly Estimates, Maintains Profit Outlook as Medical Costs Stay in Line

Humana’s latest quarterly results exceeded expectations, but the health insurer’s maintained profit outlook is a reminder that rising medical costs remain a pressing concern for the industry.

The company’s second-quarter earnings beat was driven by strength across its insurance business and CenterWell healthcare services unit. CFO Celeste Mellet attributed this success to stabilizing medical cost trends and Humana’s efforts to improve health outcomes for its members. While this is welcome news, it highlights the ongoing challenge of managing rising medical costs.

The issue of increasing medical costs has plagued the industry for over two years, with companies struggling to balance higher expenses with premium revenue. Investors have been increasingly optimistic in recent times, but Humana’s unchanged profit outlook suggests that the sector may be reaching a plateau. The company’s shares fell more than 4% in premarket trading despite the solid quarter.

The influx of people seeking care they delayed during the pandemic has contributed to rising medical costs, as well as high-cost specialty drugs, which have significantly increased pharmacy medical cost trends. According to Mellet, these costs will be slightly higher next year compared to 2026.

Humana’s maintained profit outlook of at least $9 per share in 2026 may seem reassuring, but it belies the complexities of managing medical costs and balancing revenue growth with premium income. The Medicare Advantage plans sector, which Humana dominates, has been particularly affected by these trends, with insurers hiking their outlooks and trying to get a better handle on rising medical costs.

Cantor Fitzgerald analysts have expressed disappointment in Humana’s unchanged profit outlook, highlighting the sector’s struggles. Mellet has signaled that the company is watching for signs of continued decline in services such as inpatient admissions, which could help stabilize medical costs. However, pharmacy medical cost trends remain elevated, driven by drug prices and new medicines.

To improve profitability, Humana expects changes to its 2027 Medicare Advantage plans to put the company on track to reach a sustainable pretax margin of at least 3% by 2028. This will require careful management of medical costs and premium growth, as well as maintaining pricing discipline and controlling costs.

The industry’s struggles with rising medical costs are not new, but Humana’s maintained profit outlook serves as a reminder that insurers must continue to innovate and adapt to changing market conditions. While the company’s strong second-quarter results are welcome news, they also underscore the complexities of managing healthcare costs in an environment where premium revenue growth is under pressure.

As investors await further guidance from other insurers, it’s clear that Humana’s profit outlook will be closely watched for any signs of improvement or deterioration. The industry’s ongoing challenges serve as a warning: with medical cost trends remaining elevated and premium income growth uncertain, insurers must remain vigilant in their efforts to manage costs and grow revenue.

Humana’s maintained profit outlook is not cause for celebration but rather a sobering reminder of the sector’s long-term challenges. As the industry continues to navigate these complexities, investors would do well to keep a close eye on Humana’s performance – and that of its peers – in the months ahead.